Nuclear receptor superfamily: Principles of signaling

Pure and Applied Chemistry

Volumn 75, Issue 11-12, 2003, Pages 1619-1664

  Germain, Pierre ^a   Altucci, Lucia ^b   Bourguet, William ^c   Rochette Egly, Cecile ^a   Gronemeyer, Hinrich ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c CENTRE DE BIOCHIMIE STRUCTURALE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; ENZYME; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; LIGAND; METHYLTRANSFERASE; NUCLEAR RECEPTOR COACTIVATOR 2; PROTEIN P160; PROTEIN TYROSINE KINASE; RETINOID X RECEPTOR; TRANSCRIPTION FACTOR;

ACETYLATION; APOPTOSIS; CELL DEATH; CELL PROLIFERATION; CHROMATIN; CHROMATIN CONDENSATION; CONFERENCE PAPER; CRYSTAL STRUCTURE; DNA BINDING; GENETIC TRANSCRIPTION; LIGAND BINDING; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

EID: 0345874399     PISSN: 00334545     EISSN: None     Source Type: Journal    
DOI: 10.1351/pac200375111619     Document Type: Conference Paper

References (290)

1. A unified nomenclature system for the nuclear receptor superfamily [letter]. Cell 97, 161-163 (1999).
2. M. Robinson-Rechavi, A. S. Carpentier, M. Duffraisse, V. Laudet. "How many nuclear hormone receptors are there in the human genome?", Trends Genet. 17, 554-556 (2001).
3. J. M. Maglich et al. "Comparison of complete nuclear receptor sets from the human, Caenorhabditis elegans and Drosophila genomes", Genome Biol. 2 (2001).
4. P. A. Chambon. "Decade of molecular biology of retinoic acid receptors", FASEB J. 10, 940-954 (1996).
5. V. Laudet and H. Gronemeyer. The Nuclear Receptor Facts Book, Academic Press, San Diego (2002).
6. T. T. Lu, J. J. Repa, D. J. Mangelsdorf. "Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism", J. Biol. Chem. 276, 37735-37738 (2001).
7. W. Xie and R. M. Evans. "Orphan nuclear receptors: the exotics of xenobiotics", J. Biol. Chem. 276, 37739-37742 (2001).
8. G. B. Tremblay, D. Bergeron, V. Giguere. "4-Hydroxytamoxifen is an isoform-specific inhibitor of orphan estrogen-receptor-related (ERR) nuclear receptors beta and gamma", Endocrinology 142, 4572-4575 (2001).
9. G. B. Tremblay et al. "Diethylstilbestrol regulates trophoblast stem cell differentiation as a ligand of orphan nuclear receptor ERR beta", Genes Dev. 15, 833-838 (2001).
10. T. M. Willson and S. A. Kliewer. "PXR, CAR and drug metabolism", Nat. Rev. Drug Discov. 1, 259-266 (2002).
11. X. Luo, Y. Ikeda, K. L. Parker. "A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation", Cell 77, 481-490 (1994).
12. Y. Barak et al. "PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell 4, 585-595 (1999).
13. B. Mascrez et al. "The RXRalpha ligand-dependent activation function 2 (AF-2) is important for mouse development", Development 125, 4691-4707 (1998).
14. M. Beato, P. Herrlich, G. Schutz. "Steroid hormone receptors: many actors in search of a plot", Cell 83, 851-857 (1995).
15. P. Kastner, M. Mark, P. Chambon. "Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life?", Cell 83, 859-869 (1995).
16. M. Y. Chiang et al. "An essential role for retinoid receptors RARbeta and RXRgamma in long-term potentiation and depression", Neuron 21, 1353-1361 (1998).
17. H. M. Reichardt et al. "DNA binding of the glucocorticoid receptor is not essential for survival", Cell 93, 531-541 (1998).
18. A. Krust et al. "The chicken oestrogen receptor sequence: homology with v-erbA and the human oestrogen and glucocorticoid receptors", EMBO J. 5, 891-897 (1986).
19. M. T. Bocquel, V. Kumar, C. Stricker, P. Chambon, H. Gronemeyer. "The contribution of the N-and C-terminal regions of steroid receptors to activation of transcription is both receptor and cell-specific", Nucleic Acids Res. 17, 2581-2595 (1989).
20. M. Berry, D. Metzger, P. Chambon. "Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen", EMBO J. 9, 2811-2818 (1990).
21. C. A. Sartorius et al. "A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform", Mol. Endocrinol. 8, 1347-1360 (1994).
22. S. Kato et al. "Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase", Science 270, 1491-1494 (1995).
23. M. Watanabe et al. "A subfamily of RNA-binding DEAD-box proteins acts as an estrogen receptor alpha coactivator through the N-terminal activation domain (AF-1) with an RNA coactivator, SRA", EMBO J. 20, 1341-1352 (2001).
24. T. Ylikomi, M. T. Bocquel, M. Berry, H. Gronemeyer, P. Chambon. "Cooperation of proto-signals for nuclear accumulation of estrogen and progesterone receptors", EMBO J. 11, 3681-3694 (1992).
25. A. Guiochon-Mantel, K. Delabre, P. Lescop, E. Milgrorn. "Nuclear localization signals also mediate the outward movement of proteins from the nucleus", Proc. Natl. Acad. Sci. USA 91, 7179-7183 (1994).
26. D. Walker, H. Htun, G. L. Hager. "Using inducible vectors to study intracellular trafficking of GFP-tagged steroid/nuclear receptors in living cells", Methods 19, 386-393 (1999).
27. G. L. Hager, C. S. Lim, C. Elbi, C. T. Baumann. "Trafficking of nuclear receptors in living cells", J. Steroid Biochem. Mol. Biol. 74, 249-254 (2000).
28. G. A. Peters and S. A. Khan. "Estrogen receptor domains E and F: role in dimerization and interaction with coactivator RIP-140", Mol. Endocrinol. 13, 286-296 (1999).
29. F. M. Sladek, M. D. Ruse, Jr., L. Nepomuceno, S. M. Huang, M. R. Stallcup. "Modulation of transcriptional activation and coactivator interaction by a splicing variation in the F domain of nuclear receptor hepatocyte nuclear factor 4alpha1", Mol. Cell Biol. 19, 6509-6522 (1999).
30. M. M. Montano, V. Muller, A. Trobaugh, B. S. Katzenellenbogen. "The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists", Mol. Endocrinol. 9, 814-825 (1995).
31. M. Nichols, J. M. Rientjes, A. F. Stewart. "Different positioning of the ligand-binding domain helix 12 and the F domain of the estrogen receptor accounts for functional differences between agonists and antagonists", EMBO J. 17, 765-773 (1998).
32. K. Umesono, K. K. Murakami, C. C. Thompson, R. M. Evans. "Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors", Cell 65, 1255-1266 (1991).
33. S. A. Kliewer, K. Umesono, D. J. Noonan, R. A. Heyman, R. M. Evans. "Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors", Nature 358, 771-774 (1992).
34. S. Mader et al. "The patterns of binding of RAR, RXR and TR homo- and heterodimers to direct repeats are dictated by the binding specificites of the DNA binding domains", EMBO J. 12, 5029-5041 (1993).
35. F. Rastinejad, T. Perlmann, R. M. Evans, P. B. Sigler. "Structural determinants of nuclear receptor assembly on DNA direct repeats", Nature 375, 203-11 (1995).
36. G. Meinke and P. B. Sigler. "DNA-binding mechanism of the monomeric orphan nuclear receptor NGFI-B", Nat. Struct. Biol. 6, 471-477 (1999).
37. V. G. Thackray, B. A. Lieberman, S. K. Nordeen. "Differential gene induction by glucocorticoid and progesterone receptors", J. Steroid Biochem. Mol. Biol. 66, 171-178 (1998).
38. G. Klock, U. Strahle, G. Schutz. "Oestrogen and glucocorticoid responsive elements are closely related but distinct", Nature 329, 734-736 (1987).
39. C. K. Glass. "Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers", Endocr. Rev. 15, 391-407 (1994).
40. M. Tsai, and B. O'Malley. "Molecular mechanisms of action of steroid/thyroid receptor super-family", Ann. Rev. Biochem. 63, 451-486 (1994).
41. H. Gronemeyer and V. Laudet. "Transcription factors 3: Nuclear receptors", Protein Profile 2, 1173-1308 (1995).
42. B. Desvergne and W. Wahli. "Peroxisome proliferator-activated receptors: nuclear control of metabolism", Endocr. Rev. 20, 649-688 (1999).
43. S. A. Kliewer, J. M. Lehmann, M. V. Milburn, T. M. Willson. "The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways", Recent Prog. Horm. Res. 54, 345-367 (1999).
44. H. de The, M. M. Vivanco-Ruiz, P. Tiollais, H. Stunnenberg, A. Dejean. "Identification of a retinoic acid responsive element in the retinoic acid receptor beta gene", Nature 343, 177-180 (1990).
45. B. Hoffmann et al. "A retinoic acid receptor-specific element controls the retinoic acid receptor-beta promoter", Mol. Endocrinol. 4, 1727-1736 (1990).
46. H. M. Sucov, K. K. Murakami, R. M. Evans. "Characterization of an autoregulated response element in the mouse retinoic acid receptor type beta gene", Proc. Natl. Acad. Sci. USA 87, 5392-5396 (1990).
47. D. M. Heery, B. Pierrat, H. Gronemeyer, P. Chambon, R. Losson. "Homo- and heterodimers of the retinoid X receptor (RXR) activated transcription in yeast", Nucleic Acids Res. 22, 726-731 (1994).
48. D. J. Mangelsdorf et al. "A direct repeat in the cellular retinol-binding protein type II gene confers differential regulation by RXR and RAR", Cell 66, 555-561 (1991).
49. H. Chen, Z. Smit-McBride, S. Lewis, M. Sharif, M. L. Privalsky. "Nuclear hormone receptors involved in neoplasia: erb A exhibits a novel DNA sequence specificity determined by amino acids outside of the zinc-finger domain", Mol. Cell Biol. 13, 2366-2376 (1993).
50. H. W. Chen and M. L. Privalsky. "The erbA oncogene represses the actions of both retinoid X and retinoid A receptors but does so by distinct mechanisms", Mol. Cell Biol. 13, 5970-5980 (1993).
51. B. M. Forman, J. Casanova, B. M. Raaka, J. Ghysdael, H. H. Samuels. "Half-site spacing and orientation determines whether thyroid hormone and retinoic acid receptors and related factors bind to DNA response elements as monomers, homodimers, or heterodimers. Mol. Endocrinol. 6, 429-442 (1992).
52. C. K. Glass et al. "A c-erb-A binding site in rat growth hormone gene mediates trans-activation by thyroid hormone", Nature 329, 738-741 (1987).
53. C. K. Glass, J. M. Holloway, O. V. Devary, M. G. Rosenfeld. "The thyroid hormone receptor binds with opposite transcriptional effects to a common sequence motif in thyroid hormone and estrogen response elements", Cell 54, 313-323 (1988).
54. P. P. Harding and G. Duester. "Retinoic acid activation and thyroid hormone repression of the human alcohol dehydrogenase gene ADH3", J. Biol. Chem. 267, 14145-14150 (1992).
55. J. Burnside, D. S. Darling, F. E. Carr, W. W. Chin. "Thyroid hormone regulation of the rat glycoprotein hormone alpha-subunit gene promoter activity", J. Biol. Chem. 264, 6886-6891 (1989).
56. A. Farsetti, B. Desvergne, P. Hallenbeck, J. Robbins, V. M. Nikodem. "Characterization of myelin basic protein thyroid hormone response element and its function in the context of native and heterologous promoter", J. Biol. Chem. 267, 15784-15788 (1992).
57. M. R. Haussler et al. "The vitamin D hormone and its nuclear receptor: molecular actions and disease states. J. Endocrinol. 154 Suppl, S57-73 (1997).
58. H. F. DeLuca and C. Zierold. "Mechanisms and functions of vitamin D", Nutr. Rev. 56, S4-10; discussion S54-75 (1998).
59. S. Kersten, B. Desvergne, W. Wahli. "Roles of PPARs in health and disease", Nature 405, 421-424 (2000).
60. T. M. Willson, P. J. Brown, D. D. Sternbach, B. R. Henke. "The PPARs: from orphan receptors to drug discovery", J. Med. Chem. 43, 527-550 (2000).
61. S. Khorasanizadeh and F. Rastinejad. "Nuclear-receptor interactions on DNA-response elements", Trends BioChem. Sci. 26, 384-390 (2001).
62. F. Rastinejad, T. Wagner, Q. Zhao, S. Khorasanizadeh. "Structure of the RXR-RAR DNA-binding complex on the retinoic acid response element DR1", EMBO J. 19, 1045-1054 (2000).
63. S. Green and P. Chambon. "Oestradiol induction of a glucocorticoid-responsive gene by a chimaeric receptor", Nature 325, 75-78 (1987).
64. S. Green, V. Kumar, I. Theulaz, W. Wahli, P. Chambon. "The N-terminal DNA-binding 'zinc finger' of the oestrogen and glucocorticoid receptors determines target gene specificity", EMBO J. 7, 3037-3044 (1988).
65. M. Danielsen, L. Hinck, G. M. Ringold. "Two amino acids within the knuckle of the first zinc finger specify DNA response element activation by the glucocorticoid receptor", Cell 57, 1131-1138 (1989).
66. S. Mader, V. Kumar, H. de Verneuil, P. Chambon. "Three amino acids of the oestrogen receptor are essential to its ability to distinguish an oestrogen from a glucocorticoid-responsive element", Nature 338, 271-274 (1989).
67. K. Umesono and R. M. Evans. "Determinants of target gene specificity for steroid/thyroid hormone receptors", Cell 57, 1139-1146 (1989).
68. T. E. Wilson, T. J. Fahrner, M. Johnston, J. Milbrandt. "Identification of the DNA binding site for NGFI-B by genetic selection in yeast", Science 252, 1296-1300 (1991).
69. T. E. Wilson, T. J. Fahrner, J. Milbrandt. "The orphan receptors NGFI-B and steroidogenic factor 1 establish monomer binding as a third paradigm of nuclear receptor-DNA interaction", Mol. Cell Biol. 13, 5794-5804 (1993).
70. C. Zechel et al. "The dimerization interfaces formed between the DNA binding domains of RXR, RAR and TR determine the binding specificity and polarity of the full-length receptors to direct repeats", EMBO J. 13, 1425-1433 (1994).
71. C. Zechel, X. Q. Shen, P. Chambon, H. Gronemeyer. "Dimerization interfaces formed between the DNA binding domains determine the cooperative binding of RXR/RAR and RXR/TR heterodimers to DR5 and DR4 elements", EMBO J. 13, 1414-1424 (1994).
72. T. E. Wilson, R. E. Paulsen, K. A. Padgett, J. Milbrandt. "Participation of non-zinc finger residues in DNA binding by two nuclear orphan receptors", Science 256, 107-110 (1992).
73. M. S. Lee, S. A. Kliewer, J. Provencal, P. E. Wright, R. M. Evans. "Structure of the retinoid X receptor alpha DNA binding domain: a helix required for homodimeric DNA binding", Science 260, 1117-11121 (1993).
74. J. W. Schwabe, L. Chapman, J. T. Finch, D. Rhodes. "The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: how receptors discriminate between their response elements", Cell 75, 567-578 (1993).
75. J. M. Wurtz et al. "A canonical structure for the ligand-binding domain of nuclear receptors", [published erratum appears in Nat Struct Biol. Feb. 3 (2), 206 (1996)]. Nat. Struct. Biol. 3, 87-94 (1996).
76. J. M. Wurtz et al. "A canonical structure for the ligand-binding domain of nuclear receptors", [published erratum appears in Nat Struct Biol. Feb. 3 (2), 206 (1996)]. Nat. Struct. Biol. 3, 87-94 (1996).
77. J. P. Renaud et al. "Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature 378, 681-689 (1995).
78. R. T. Nolte et al. "Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma", Nature 395, 137-143 (1998).
79. R. White, M. Sjoberg, E. Kalkhoven, M. G. Parker. " Ligand-independent activation of the oestrogen receptor by mutation of a conserved tyrosine", EMBO J. 16, 1427-1435 (1997).
80. J. J. Voegel et al. "The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways", EMBO J. 17, 507-519 (1998).
81. K. E. Weis, K. Ekena, J. A. Thomas, G. Lazennec, B. S. Katzenellenbogen, "Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol. Endocrinol. 10, 1388-1398 (1996).
82. V. Vivat et al. "A mutation mimicking ligand-induced conformational change yields a constitutive RXR that senses allosteric effects in heterodimers", EMBO J. 16, 5697-5709 (1997).
83. W. Bourguet et al. Crystal structure of a heterodimeric complex of RAR and RXR ligand - binding domains", Mol. Cell 5, 289-298 (2000).
84. R. T. Gampe, Jr. et al. "Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors", Mol. Cell 5, 545-555 (2000).
85. W. Bourguet, M. Ruff, P. Chambon, H. Gronemeyer, D. Moras. "Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha", Nature 375, 377-382 (1995).
86. A. M. Brzozowski et al. "Molecular basis of agonism and antagonism in the oestrogen receptor", Nature 389, 753-758 (1997).
87. R. K. Bledsoe et al. "Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition", Cell 110, 93-105 (2002).
88. B. P. Klaholz et al. "Conformational adaptation of agonists to the human nuclear receptor RAR gamma", Nat. Struct. Biol. 5, 199-202 (1998).
89. R. E. Watkins et al. "The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity", Science 292, 2329-2333 (2001).
90. J. D. Chen. "Steroid/nuclear receptor coactivators", Vitam. Horm. 58, 391-448 (2000).
91. C. K. Glass and M. G. Rosenfeld. "The coregulator exchange in transcriptional functions of nuclear receptors", Genes Dev. 14, 121-141 (2000).
92. H. Chen, M. Tini, R. M. Evans. "HATs on and beyond chromatin", Curr. Opin. Cell Biol. 13, 218-224 (2001).
93. O. Hermanson, C. K. Glass, M. G. Rosenfeld. "Nuclear receptor coregulators: multiple modes of modification", Trends Endocrinol. Metab. 13, 55-60 (2002).
94. N. J. McKenna and B. W. O'Malley. "Combinatorial control of gene expression by nuclear receptors and coregulators", Cell 108, 465-474 (2002).
95. K. Jepsen and M. G. Rosenfeld. "Biological roles and mechanistic actions of co-repressor complexes", J. Cell Sci. 115, 689-698 (2002).
96. A. Aranda and A. Pascual. "Nuclear hormone receptors and gene expression", Physiol. Rev. 81, 1269-1304 (2001).
97. K. C. Lee and W. Lee Kraus. "Nuclear receptors, coactivators and chromatin: new approaches, new insights", Trends Endocrinol. Metab. 12, 191-197 (2001).
98. M. Ito and R. G. Roeder. The TRAP/SMCC/Mediator complex and thyroid hormone receptor function", Trends Endocrinol. Metab. 12, 127-134 (2001).
99. J. W. Lee, Y. C. Lee, S. Y. Na, D. J. Jung, S. K. Lee. "Transcriptional coregulators of the nuclear receptor superfamily: coactivators and corepressors", Cell Mol. Life Sci. 58, 289-297 (2001).
100. P. Ordentlich, M. Downes, R. M. Evans. "Corepressors and nuclear hormone receptor function", Curr. Top. Microbiol. Immunol. 254, 101-116 (2001).
101. M. G. Rosenfeld and C. K. Glass. Coregulator codes of transcriptional regulation by nuclear receptors", J. Biol. Chem. 276, 36865-36868 (2001).
102. O. M. Conneely, J. P. Lydon, F. De Mayo, B. W. O'Malley. "Reproductive functions of the progesterone receptor", J. Soc. Gynecol. Investig. 7, S25-32 (2000).
103. K. B. Horwitz, L. Tung, G. S. Takimoto. "Novel mechanisms of antiprogestin action", J. Steroid BioChem. Mol. Biol. 53, 9-17 (1995).
104. C. A. Lange, J. K. Richer, K. B. Horwitz. "Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals", Mol. Endocrinol. 13, 829-836 (1999).
105. D. L. Bain, M. A. Franden, J. L. McManaman, G. S. Takimoto, K. B. Horwitz. "The N-terminal region of the human progesterone A-receptor. Structural analysis and the influence of the DNA binding domain", J. Biol. Chem. 275, 7313-7320 (2000).
106. S. Nagpal et al. "Promoter context- and response element-dependent specificity of the transcriptional activation and modulating functions of retinoic acid receptors", Cell 70, 1007-1019 (1992).
107. G. Gill and M. Ptashne. "Negative effect of the transcriptional activator GAL4", Nature 334, 721-724 (1988).
108. M. E. Meyer et al. "Steroid hormone receptors compete for factors that mediate their enhancer function", Cell 57, 433-442 (1989).
109. D. Tasset, L. Tora, C. Fromental, E. Scheer, P. Chambon. "Distinct classes of transcriptional activating domains function by different mechanisms", Cell 62, 1177-1187 (1990).
110. B. Le Douarin et al. "A possible involvement of TIF1 alpha and TIF1 beta in the epigenetic control of transcription by nuclear receptors", EMBO J. 15, 6701-6715 (1996).
111. D. M. Heery, E. Kalkhoven, S. Hoare, M. G. Parker. "A signature motif in transcriptional co-activators mediates binding to nuclear receptor", Nature 387, 733-736 (1997).
112. J. Torchia et al. "The transcriptional co-activator p/CIP binds CBP and mediates nuclear- receptor function", Nature 387, 677-684 (1997).
113. Y. Shang, X. Hu, J. DiRenzo, M. A. Lazar, M. Brown. "Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription", Cell 103, 843-852 (2000).
114. L. P. Freedman. "Increasing the complexity of coactivation in nuclear receptor signaling", Cell 97, 5-8 (1999).
115. C. A. Berrevoets, P. Doesburg, K. Steketee, J. Trapman, A. O. Brinkmann. "Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2)", Mol. Endocrinol. 12, 1172-1183 (1998).
116. P. Alen, F. Claessens, G. Verhoeven, W. Rombauts, B. Peeters. "The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription", Mol. Cell Biol. 19, 6085-6097 (1999).
117. C. L. Bevan, S. Hoare, F. Claessens, D. M. Heery, M. G. Parker. "The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1", Mol. Cell Biol. 19, 8383-8392 (1999).
118. B. He, J. A. Kemppainen, J. J. Voegel, H. Gronemeyer, E. M. Wilson. "Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain", J. Biol. Chem. 274, 37219-37225 (1999).
119. H. Ma et al. "Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins", Mol. Cell Biol. 19, 6164-6173 (1999).
120. E. M. Mcinerney, M. J. Tsai, B. W. Omalley, B. S. Katzenellenbogen. "Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator", Proc. Natl. Acad. Sci. USA 93, 10069-10073 (1996).
121. A. Benecke, P. Chambon, H. Gronemeyer. "Synergy between estrogen receptor a activation functions AF1 and AF2 mediated by transcription intermediary factor TIF2", EMBO Reports 1, 151-157 (2000).
122. H. Chen, R. J. Lin, W. Xie, D. Wilpitz, R. M. Evans. "Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase", Cell 98, 675-686 (1999).
123. D. Chen et al. "Regulation of transcription by a protein methyltransferase", Science 284, 2174-2177 (1999).
124. N. Kotaja, U. Karvonen, O. A. Janne, J. J. Palvimo. "The nuclear receptor interaction domain of GRIPI is modulated by covalent attachment of SUMO-1", J. Biol. Chem. 277, 30283-30288 (2002).
125. A. M. Jimenez-Lara, M. J. Heine, H. Gronemeyer. "PIAS3 (protein inhibitor of activated STAT-3) modulates the transcriptional activation mediated by the nuclear receptor Coactivator TIF2", FEBS Lett. 526, 142-146 (2002).
126. A. M. Jimenez-Lara, M. J. Heine, H. Gronemeyer. "Cloning of a mouse glucocorticoid modulatory element binding protein, a new member of the KDWK family", FEBS Lett. 468, 203-210 (2000).
127. S. M. Huang and M. R. Stallcup. "Mouse Zac1, a transcriptional coactivator and repressor for nuclear receptors", Mol. Cell Biol. 20, 1855-1867 (2000).
128. P. M. A. Henttu, E. Kalkhoven, M. G. Parker. "AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors", Mol. Cell Biol. 17, 1832-1839 (1997).
129. W. Feng et al. "Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors", Science 280, 1747-1749 (1998).
130. B. D. Darimont et al. "Structure and specificity of nuclear receptor-coactivator interactions", Genes Dev. 12, 3343-3356 (1998).
131. A. K. Shiau et al. "The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95, 927-937 (1998).
132. E. M. McInerney et al. "Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation", Genes Dev. 12, 3357-3368 (1998).
133. X. Hu and M. A. Lazar. "The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors", Nature 402, 93-96 (1999).
134. L. Nagy et al. "Mechanism of corepressor binding and release from nuclear hormone receptors", Genes Dev. 13, 3209-3216 (1999).
135. V. Perissi et al. "Molecular determinants of nuclear receptor-corepressor interaction", Genes Dev. 13, 3198-3208 (1999).
136. H. E. Xu et al. "Structural basis for antagonist-mediated recruitment of nuclear co- repressors by PPARalpha", Nature 415, 813-817 (2002).
137. T. A. Jackson et al. "The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT", Mol. Endocrinol. 11, 693-705 (1997).
138. B. L. Wagner, J. D. Norris, T. A. Knotts, N. L. Weigel, D. P. McDonnell. "The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor", Mol. Cell Biol. 18, 1369-1378 (1998).
139. X. Zhang, M. Jeyakumar, S. Petukhov, M. K. Bagchi. "A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor", Mol. Endocrinol. 12, 513-524 (1998).
140. A. J. Horlein et al. "Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor", Nature 377, 397-404 (1995).
141. R. Kurokawa et al. "Differential use of CREB binding protein-coactivator complexes", Science 279, 700-703 (1998).
142. J. P. Renaud, J. M. Harris, M. Downes, L. J. Burke, G. E. Muscat. "Structure-function analysis of the Rev-erbA and RVR ligand-binding domains reveals a large hydrophobic surface that mediates corepressor binding and a ligand cavity occupied by side chains", Mol. Endocrinol. 14, 700-717 (2000).
143. W. Seol, M. J. Mahon, Y. K. Lee, D. D. Moore. "Two receptor interacting domains in the nuclear hormone receptor corepressor RIP 13/N-CoR", Mol. Endocrinol. 10, 1646-1655 (1996).
144. I. Zamir et al. "A nuclear hormone receptor corepressor mediates transcriptional silencing by receptors with distinct repression domains", Mol. Cell Biol. 16, 5458-5465 (1996).
145. J. D. Fondell, H. Ge, R. G. Roeder. "Ligand induction of a transcriptionally active thyroid hormone receptor coactivator complex", Proc. Natl. Acad. Sci. USA 93, 8329-8333 (1996).
146. C. Rachez et al. "A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell- free system", Genes Dev. 12, 1787-1800 (1998).
147. M. Ito et al. "Identity between TRAP and SMCC complexes indicates novel pathways for the function of nuclear receptors and diverse mammalian activators", Mol. Cell 3, 361-370 (1999).
148. W. Gu et al. "A novel human SRB/MED-containing cofactor complex, SMCC, involved in transcription regulation", [published erratum appears in Mol. Cell April 3 (4), following 541 (1999)]. Mol. Cell 3, 97-108 (1999).
149. W. Gu et al. "A novel human SRB/MED-containing cofactor complex, SMCC, involved in transcription regulation", [published erratum appears in Mol. Cell April 3 (4), following 541 (1999)]. Mol. Cell 3, 97-108 (1999).
150. M. Kretzschmar, G. Stelzer, R. G. Roeder, M. Meisterernst. "RNA polymerase 11 cofactor PC2 facilitates activation of transcription by GAL4-AH in vitro", Mol. Cell Biol. 14, 3927-3937 (1994).
151. A. M. Naar et al. "Composite co-activator ARC mediates chromatin-directed transcriptional activation", Nature 398, 828-832 (1999).
152. S. Ryu and R. Tjian. Purification of transcription cofactor complex CRSP. Proc. Natl. Acad. Sci. USA 96, 7137-7142 (1999).
153. X. Sun et al. "NAT, a human complex containing Srb polypeptides that functions as a negative regulator of activated transcription", Mol. Cell 2, 213-222 (1998).
154. J. D. Fondell, M. Guermah, S. Malik, R. G. Roeder. "Thyroid hormone receptor-associated proteins and general positive cofactors mediate thyroid hormone receptor function in the absence of the TATA box-binding protein-associated factors of TFIID", Proc. Natl. Acad. Sci. USA 96, 1959-1964 (1999).
155. C. Rachez et al. "Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex", Nature 398, 824-828 (1999).
156. W. Yang and L. P. Freedman. "20-Epi analogues of 1,25-dihydroxyvitamin D3 are highly potent inducers of DRIP coactivator complex binding to the vitamin D3 receptor", J. Biol. Chem. 274, 16838-16845 (1999).
157. C. X. Yuan, M. Ito, J. D. Fondell, Z. Y. Fu, R. G. Roeder. "The TRAP220 component of a thyroid hormone receptor-associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion", [published erratum appears in Proc. Natl. Acad. Sci. USA Nov 24; 95 (24), 14584 (1998)]. Proc. Natl. Acad. Sci. USA 95, 7939-7944 (1998).
158. C. X. Yuan, M. Ito, J. D. Fondell, Z. Y. Fu, R. G. Roeder. "The TRAP220 component of a thyroid hormone receptor-associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion", [published erratum appears in Proc. Natl. Acad. Sci. USA Nov 24; 95 (24), 14584 (1998)]. Proc. Natl. Acad. Sci. USA 95, 7939-7944 (1998).
159. A. B. Hittelman, D. Burakov, J. A. Iniguez-Lluhi, L. P. Freedman, M. J. Garabedian. "Differential regulation of glucocorticoid receptor transcriptional activation via AF-1-associated proteins", EMBO J. 18, 5380-5388 (1999).
160. M. Gehin et al. "Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists", Chem. Biol. 6, 519-529 (1999).
161. S. Minucci et al. "Retinoid X receptor (RXR) within the RXR-retinoic acid receptor heterodimer binds its ligand and enhances retinoid-dependent gene expression", Mol. Cell Biol. 17, 644-655 (1997).
162. J. Y. Chen et al. "Two distinct actions of retinoid-receptor ligands", Nature 382, 819-822 (1996).
163. A. C. Pike et al. "Structural insights into the mode of action of a pure antiestrogen", Structure (Camb.) 9, 145-153 (2001).
164. J. L. Oberfield et al. "A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation", Proc. Natl. Acad. Sci. USA 96, 6102-6106 (1999).
165. A. K. Shiau et al. "Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism", Nat. Struct. Biol. 9, 359-364 (2002).
166. R. M. Lavinsky et al. "Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes", Proc. Natl. Acad. Sci. USA 95, 2920-2925 (1998).
167. P. Germain, J. Iyer, C. Zechel, H. Gronemeyer. "Coregulator recruitment and the mechanism of retinoic acid receptor synergy", Nature 415, 187-192 (2002).
168. E. S. Klein et al. "Identification and functional separation of retinoic acid receptor neutral antagonists and inverse agonists", J. Biol. Chem. 271, 22692-22696 (1996).
169. J. Clifford, H. Chiba, D. Sobieszczuk, D. Metzger, P. Chambon. "RXRalpha-null F9 embryonal carcinoma cells are resistant to the differentiation, anti-proliferative and apoptotic effects of retinoids", EMBO J. 15, 4142-4155 (1996).
170. R. Taneja et al. "Cell-type and promoter-context dependent retinoic acid receptor (RAR) redundancies for RAR beta 2 and Hoxa-1 activation in F9 and P19 cells can be artefactually generated by gene knockouts", Proc. Natl. Acad. Sci. USA 93, 6197-6202 (1996).
171. R. Kurokawa et al. "Regulation of retinoid signalling by receptor polarity and allosteric control of ligand binding", Nature 371, 528-531 (1994).
172. C. M. Apfel et al. "Enhancement of HL-60 differentiation by a new class of retinoids with selective activity on retinoid X receptor", J. Biol. Chem. 270, 30765-30772 (1995).
173. Z. Chen et al. "Ligand- And DNA-induced Dissociation of RXR Tetramers", J. Mol. Biol. 275, 55-65 (1998).
174. S. Kersten, M. I. Dawson, B. A. Lewis, N. Noy. "Individual subunits of heterodimers comprised of retinoic acid and retinoid X receptors interact with their ligands independently", Biochemistry 35, 3816-3824 (1996).
175. H. Li, P. J. Gomes, J. D. Chen. "RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2", Proc. Natl. Acad. Sci. USA 94, 8479-8484 (1997).
176. B. M. Forman, K. Umesono, J. Chen, R. M. Evans. "Unique response pathways are established by allosteric interactions among nuclear hormone receptors", Cell 81, 541-550 (1995).
177. T. Perlmann and L. Jansson. "A novel pathway for vitamin A signaling mediated by RXR heterodimerization with NGFI-B and NURR1", Genes Dev. 9, 769-782 (1995).
178. B. Blumberg and R. M. Evans. "Orphan nuclear receptors - new ligands and new possibilities", Genes Dev. 12, 3149-3155 (1998).
179. M. Fu et al. "Androgen receptor acetylation governs trans activation and MEKK1- induced apoptosis without affecting in vitro sumoylation and trans- repression function", Mol. Cell Biol. 22, 3373-3388 (2002).
180. C. Wang et al. "Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity", J. Biol. Chem. 276, 18375-18383 (2001).
181. T. Kouzarides. "Acetylation: a regulatory modification to rival phosphorylation?", EMBO J. 19, 1176-1179 (2000).
182. D. O. Morgan. "Principles of CDK regulation", Nature 374, 131-134 (1995).
183. D. O. Morgan. "Cyclin-dependent kinases: Engines, clocks, and microprocessors", Ann. Rev. Cell Dev. Biol. 13, 261-291 (1997).
184. Z. Chen et al. "MAP kinases", Chem. Rev. 101, 2449-2476 (2001).
185. G. Pearson et al. "Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions", Endocr. Rev. 22, 153-183 (2001).
186. L. Chang and M. Karin. "Mammalian MAP kinase signalling cascades", Nature 410, 37-40 (2001).
187. N. L. Weigel. "Steroid hormone receptors and their regulation by phosphorylation", BioChem. J. 319, 657-667 (1996).
188. T. Shen, K. B. Horwitz, C. A. Lange. "Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294", Mol. Cell Biol. 21, 6122-31 (2001).
189. G. Bunone, P. A. Briand, R. J. Miksicek, D. Picard. "Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation", EMBO J. 15, 2174-2183 (1996).
190. P. H. Driggers, J. H. Segars, D. M. Rubino. "The proto-oncoprotein Brx activates estrogen receptor beta by a p38 mitogen-activated protein kinase pathway", J. Biol. Chem. 276, 46792-46797 (2001).
191. A. Tremblay, G. B. Tremblay, F. Labrie, V. Giguere. " Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1", Mol. Cell 3, 513-519 (1999).
192. S. Yeh et al. "From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells", Proc. Natl. Acad. Sci. USA 96, 5458-5463 (1999).
193. E. Hu, J. B. Kim, P. Sarraf, B. M. Spiegelman. "Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma", Science 274, 2100-2103 (1996).
194. C. E. Juge-Aubry et al. "Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor alpha by phosphorylation of a ligand- independent trans-activating domain", J. Biol. Chem. 274, 10505-10510 (1999).
195. M. Gianni, A. Bauer, E. Garattini, P. Chambon, C. Rochette-Egly. "Phosphorylation by p38MAPK and recruitment of SUG-1 are required for RA- induced RARgamma degradation and transactivation", EMBO J. 21, 3760-3769 (2002).
196. M. Gianni et al. "Down-regulation of the phosphatidylinositol 3-kinase/Akt pathway is involved in retinoic acid-induced phosphorylation, degradation, and transcriptional activity of retinoic acid receptor gamma 2", J. Biol. Chem. 277, 24859-24862 (2002).
197. S. Adam-Stitah, L. Penna, P. Chambon, C. Rochette-Egly. "Hyperphosphorylation of the retinoid X receptor alpha by activated c- Jun NH2-terminal kinases", J. Biol. Chem. 274, 18932-18941 (1999).
198. H. Y. Lee et al. "Stress pathway activation induces phosphorylation of retinoid X receptor", J. Biol. Chem. 275, 32193-32199 (2000).
199. M. P. Scheid and J. R. Woodgett. "PKB/AKT: functional insights from genetic models", Nat. Rev. Mol. Cell Biol. 2, 760-768 (2001).
200. R. A. Campbell et al. "Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance", J. Biol. Chem. 276, 9817-9824 (2001).
201. H. K. Lin, S. Yeh, H. Y. Kang, C. Chang. "Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor", Proc. Natl. Acad. Sci. USA 98, 7200-7205 (2001).
202. A. Migliaccio, M. Pagano, F. Auricchio. "Immediate and transient stimulation of protein tyrosine phosphorylation by estradiol in MCF-7 cells", Oncogene 8, 2183-2191 (1993).
203. C. Rochette-Egly et al. Phosphorylation of the retinoic acid receptor-alpha by protein kinase A. Mol. Endocrinol. 9, 860-871 (1995).
204. J. I. Huggenvik, M. W. Collard, Y. W. Kim, R. P. Sharma. "Modification of the retinoic acid signaling pathway by the catalytic subunit of protein kinase-A", Mol. Endocrinol. 7, 543-550 (1993).
205. D. Chen, P. E. Pace, R. C. Coombes, S. Ali. "Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization", Mol. Cell Biol. 19, 1002-1015 (1999).
206. M. H. Delmotte, A. Tahayato, P. Formstecher, P. Lefebvre. "Serine 157, a retinoic acid receptor alpha residue phosphorylated by protein kinase C in vitro, is involved in RXR.RARalpha heterodimerization and transcriptional activity", J. Biol. Chem. 274, 38225-38231 (1999).
207. J. C. Hsieh et al. "Phosphorylation of the human vitamin D receptor by protein kinase C. Biochemical and functional evaluation of the serine 51 recognition site. J. Biol. Chem. 268, 15118-15126 (1993).
208. J. M. Egly. "The 14th Datta Lecture. TFIIH: from transcription to clinic", FEBS Lett. 498, 124-128 (2001).
209. D. Chen et al. "Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7", Mol. Cell 6, 127-137 (2000).
210. J. M. Trowbridge, I. Rogatsky, M. J. Garabedian. "Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex", Proc. Natl. Acad. Sci. USA 94, 10132-10137 (1997).
211. C. Rochette-Egly, S. Adam, M. Rossignol, J. M. Egly, P. Chambon. "Stimulation of RAR alpha activation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK7", Cell 90, 97-107 (1997).
212. J. Bastien et al. "TFIIH interacts with the retinoic acid receptor gamma and phosphorylates its AF-1-activating domain through cdk7", J. Biol. Chem. 275, 21896-21904 (2000).
213. D. K. Lee, H. O. Duan, C. Chang. "From androgen receptor to the general transcription factor TFIIH. Identification of cdk activating kinase (CAK) as an androgen receptor NH(2)-terminal associated coactivator", J. Biol. Chem. 275, 9308-9313 (2000).
214. A. Keriel, A. Stary, A. Sarasin, C. Rochette-Egly, J. M. Egly. "XPD mutations prevent TFIIH-dependent transactivation by nuclear receptors and phosphorylation of RARalpha", Cell 109, 125-135 (2002).
215. C. Rochette-Egly and P. Chambon. "F9 embryocarcinoma cells: a cell autonomous model to study the functional selectivity of RARs and RXRs in retinoid signaling", Histol. Histopathol. 16, 909-922 (2001).
216. R. Taneja et al. "Phosphorylation of activation functions AF-1 and AF-2 of RAR alpha and RAR gamma is indispensable for differentiation of F9 cells upon retinoic acid and cAMP treatment", EMBO J. 16, 6452-6465 (1997).
217. E. Kopf et al. "Dimerization with retinoid X receptors and phosphorylation modulate the retinoic acid-induced degradation of retinoic acid receptors alpha and gamma through the ubiquitin-proteasome pathway", J. Biol. Chem. 275, 33280-33288 (2000).
218. S. F. Arnold, M. Melamed, D. P. Vorojeikina, A. C. Notides, S. Sasson. "Estradiol-binding mechanism and binding capacity of the human estrogen receptor is regulated by tyrosine phosphorylation", Mol. Endocrinol. 11, 48-53 (1997).
219. C. Rochette-Egly, J. L. Plassat, R. Taneja, P. Chambon. "The AF-1 and AF-2 activating domains of retinoic acid receptor-alpha (RARalpha) and their phosphorylation are differentially involved in parietal endodermal differentiation of F9 cells and retinoid-induced expression of target genes", Mol. Endocrinol. 14, 1398-1410 (2000).
220. B. G. Rowan, N. L. Weigel, B. W. O'Malley. "Phosphorylation of steroid receptor coactivator-1. Identification of the phosphorylation sites and phosphorylation through the mitogen- activated protein kinase pathway", J. Biol. Chem. 275, 4475-4483 (2000).
221. G. N. Lopez, C. W. Turck, F. Schaufele, M. R. Stallcup, P. J. Kushner. "Growth factors signal to steroid receptors through mitogen-activated protein kinase regulation of p160 coactivator activity", J. Biol. Chem. 276, 22177-22182 (2001).
222. D. Knutti, D. Kressler, A. Kralli. "Regulation of the transcriptional coactivator PGC-1 via MAPK-sensitive interaction with a repressor", Proc. Natl. Acad. Sci. USA 98, 9713-9718 (2001).
223. J. Font de Mora and M. Brown. "AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor", Mol. Cell Biol. 20, 5041-5047 (2000).
224. N. Vo and R. H. Goodman. "CREB-binding protein and p300 in transcriptional regulation", J. Biol. Chem. 276, 13505-13508 (2001).
225. L. W. Yuan and J. E. Gambee. "Phosphorylation of p300 at serine 89 by protein kinase C", J. Biol. Chem. 275, 40946-40951 (2000),
226. S. H. Hong and M. L. Privalsky. "The SMRT corepressor is regulated by a MEK-1 kinase pathway: inhibition of corepressor function is associated with SMRT phosphorylation and nuclear export", Mol. Cell Biol. 20, 6612-6625 (2000).
227. M. Resche-Rigon and H. Gronemeyer. "Therapeutic potential of selective modulators of nuclear receptor action", Curr. Opin. Chem. Biol. 2, 501-507 (1998).
228. M. I. Diamond, J. N. Miner, S. K. Yoshinaga, K. R. Yamamoto. "Transcription factor interactions: selectors of positive or negative regulation from a single DNA element", Science 249, 1266-1272 (1990).
229. C. Jonat et al. "Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone", Cell 62, 1189-1204 (1990).
230. H. F. Yang-Yen et al. "Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction", Cell 62, 1205-1215 (1990).
231. L. Shemshedini, R. Knauthe, P. Sassone-Corsi, A. Pornon, H. Gronemeyer. "Cell-specific inhibitory and stimulatory effects of Fos and Jun on transcription activation by nuclear receptors", EMBO J. 10, 3839-3849 (1991).
232. A. Bubulya, S. C. Wise, X. Q. Shen, L. A. Burmeister, L. Shemshedini. "c-Jun can mediate androgen receptor-induced transactivation", J. Biol. Chem. 271, 24583-24589 (1996).
233. D. Pearce, W. Matsui, J. N. Miner, K. R. Yamamoto. "Glucocorticoid receptor transcriptional activity determined by spacing of receptor and nonreceptor DNA sites", J. Biol. Chem. 273, 30081-30085 (1998).
234. Y. Kamei et al. "A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors", Cell 85, 403-414 (1996).
235. K. De Bosscher, W. Vanden Berghe, G. Haegeman. "Glucocorticoid repression of AP-1 is not mediated by competition for nuclear coactivators", Mol. Endocrinol. 15, 219-227 (2001).
236. J. Y. Chen et al. "RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation", EMBO J. 14, 1187-97 (1995).
237. C. Caelles, J. M. Gonzalez-Sancho, A. Munoz. "Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway", Genes Dev. 11, 3351-3364 (1997).
238. X. F. Zhou, X. Q. Shen, L. Shemshedini. Ligand-activated retinoic acid receptor inhibits AP-1 transactivation by disrupting c-Jun/c-Fos dimerization", Mol. Endocrinol. 13, 276-285 (1999).
239. P. Webb, G. N. Lopez, R. M. Uht, P. J. Kushner. "Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens", Mol. Endocrinol. 9, 443-456 (1995).
240. M. Gottlicher, S. Heck, P. Herrlich. "Transcriptional cross-talk, the second mode of steroid hormone receptor action", J. Mol. Med. 76, 480-489 (1998).
241. N. Auphan, J. A. DiDonato, C. Rosette, A. Helmberg, M. Karin. "Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis", Science 270, 286-290 (1995).
242. S. Heck et al. I kappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid receptor", EMBO J. 16, 4698-4707 (1997).
243. K. De Bosscher et al. "Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell", Proc. Natl. Acad. Sci. USA 97, 3919-3924 (2000).
244. P. Delerive et al. "DNA Binding-Independent Induction of IkappaBalpha Gene Transcription by PPARalpha", Mol. Endocrinol. 16, 1029-1039 (2002).
245. I. Barroso et al. "Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension", Nature 402, 880-883 (1999).
246. Z. Wang, G. Sun, Z. Shen, S. Chen, Z. Chen. "Differentiation therapy for acute promyelocytic leukemia with all-trans retinoic acid: 10-year experience of its clinical application", Chin. Med. J. (Engl.) 112, 963-967 (1999).
247. L. Degos and Z. Y. Wang. "All trans retinoic acid in acute promyelocytic leukemia. Oncogene 20, 7140-7145 (2001).
248. L. Altucci and H. Gronemeyer. "The promise of retinoids to fight against cancer", Nat. Rev. Cancer 1, 181-193 (2001).
249. L. Altucci and H. Gronemeyer. "Nuclear receptors in cell life and death", Trends Endocrinol. Metab. 12, 460-468 (2001).
250. M. B. Sporn and N. Suh. "Opinion: Chemoprevention: an essential approach to controlling cancer. Nat. Rev. Cancer 2, 537-543 (2002).
251. S. Refetoff, R. E. Weiss, S. J. Usala. "The syndromes of resistance to thyroid hormone", Endocr. Rev. 14, 348-399 (1993).
252. S. J. Usala et al. "A homozygous deletion in the c-erbA beta thyroid hormone receptor gene in a patient with generalized thyroid hormone resistance: isolation and characterization of the mutant receptor", Mol. Endocrinol. 5, 327-335 (1991).
253. S. J. Usala et al. "A base mutation of the C-erbA beta thyroid hormone receptor in a kindred with generalized thyroid hormone resistance. Molecular heterogeneity in two other kindreds", J. Clin. Invest. 85, 93-100 (1990).
254. T. N. Collingwood et al. "A role for helix 3 of the TRbeta ligand-binding domain in coactivator recruitment identified by characterization of a third cluster of mutations in resistance to thyroid hormone", EMBO J. 17, 4760-4770 (1998).
255. T. N. Collingwood, M. Adams, Y. Tone, V. K. Chatterjee. "Spectrum of transcriptional, dimerization, and dominant negative properties of twenty different mutant thyroid hormone beta-receptors in thyroid hormone resistance syndrome", Mol. Endocrinol. 8, 1262-1277 (1994).
256. R. E. Weiss et al. "Dominant inheritance of resistance to thyroid hormone not linked to defects in the thyroid hormone receptor alpha or beta genes may be due to a defective cofactor", J. Clin. Endocrinol. Metab. 81, 4196-4203 (1996).
257. J. D. Safer, R. N. Cohen, A. N. Hollenberg, F. E. Wondisford. "Defective release of corepressor by hinge mutants of the thyroid hormone receptor found in patients with resistance to thyroid hormone", J. Biol. Chem. 273, 30175-30182 (1998).
258. M. Alcalay et al. "Common themes in the pathogenesis of acute myeloid leukemia", Oncogene 20, 5680-5694 (2001).
259. H. de The and M. K. Chelbi-Alix. "APL, a model disease for cancer therapies?", Oncogene 20, 7136-7139 (2001).
260. F. Piazza, C. Gurrieri, P. P. Pandolfi. "The theory of APL. Oncogene 20, 7216-7122 (2001).
261. E. M. Rego and P. P. Pandolfi. "Reciprocal products of chromosomal translocations in human cancer pathogenesis: key players or innocent bystanders?", Trends. Mol. Med. 8, 396-405 (2002).
262. F. Grignani et al. "Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia", Nature 391, 815-818 (1998).
263. L. Z. He et al. "Distinct interactions of PML-RARalpha and PLZF-RARalpha with co- repressors determine differential responses to RA in APL", Nat. Genet. 18, 126-135 (1998).
264. R. J. Lin et al. "Role of the histone deacetylase complex in acute promyelocytic leukaemia", Nature 391, 811-814 (1998).
265. W. Bourguet, P. Germain, H. Gronemeyer. "Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications", Trends Pharmacol. Sci. 21, 381-388 (2000).
266. L. Altucci et al. "Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL", Nat. Med. 7, 680-686 (2001).
267. L. E. French and J. Tschopp. The TRAIL to selective tumor death [news; comment]. Nat. Med. 5, 146-147 (1999).
268. M. Ristow, D. Muller-Wieland, A. Pfeiffer, W. Krone, C. R. Kahn. "Obesity associated with a mutation in a genetic regulator of adipocyte differentiation", N. Engl. J. Med. 339, 953-959 (1998).
269. M. W. Schwartz and S. E. Kahn. "Insulin resistance and obesity", Nature 402, 860-861 (1999).
270. D. Altshuler et al. "The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes", Nat. Genet. 26, 76-80 (2000).
271. P. Sarraf et al. "Loss-of-function mutations in PPAR gamma associated with human colon cancer", Mol. Cell 3, 799-804 (1999).
272. M. R. Hughes et al. "Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets", Science 242, 1702-1705 (1988).
273. H. H. Ritchie et al. "An ochre mutation in the vitamin D receptor gene causes hereditary 1,25- dihydroxyvitamin D3-resistant rickets in three families", Proc. Natl. Acad. Sci. USA 86, 9783-9787 (1989).
274. T. Carling et al. "Vitamin D receptor genotypes in primary hyperparathyroidism", Nat. Med. 1, 1309-1311 (1995).
275. E. P. Smith et al. "Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man", N. Engl. J. Med 331, 1056-1061 (1994).
276. T. A. Hopp and S. A. Fuqua. "Estrogen receptor variants. J. Mammary Gland Biol. Neoplasia 3, 73-83 (1998).
277. A. R. La Spada, E. M. Wilson, D. B. Lubahn, A. E. Harding, K. H. Fischbeck. "Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy", Nature 352, 77-79 (1991).
278. A. N. Mhatre et al. "Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy", Nat. Genet. 5, 184-188 (1993).
279. X. Y. Zhao et al. "Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor", Nat. Med. 6, 703-706 (2000).
280. A. O. Brinkmann and J. Trapman. "Prostate cancer schemes for androgen escape", Nat. Med. 6, 628-629 (2000).
281. D. M. Hurley et al. "Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance", J. Clin. Invest. 87, 680-686 (1991).
282. M. Karl et al. "Familial glucocorticoid resistance caused by a splice site deletion in the human glucocorticoid receptor gene", J. Clin. Endocrinol. Metab. 76, 683-689 (1993).
283. S. L. Anzick et al. "AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer", Science 277, 965-968 (1997).
284. M. Carapeti, R. C. Aguiar, A. E. Watmore, J. M. Goldman, N. C. Cross. "Consistent fusion of MOZ and TIF2 in AML with inv(8)(p11q13)", Cancer Genet. Cytogenet. 113, 70-72 (1999).
285. J. Liang, L. Prouty, B. J. Williams, M. A. Dayton, K. L. Blanchard. "Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2", Blood 92, 2118-2122 (1998).
286. M. Carapeti, R. C. Aguiar, J. M. Goldman, N. C. Cross. "A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia", Blood 91, 3127-3133 (1998).
287. P. Blume-Jensen and T. Hunter. "Oncogenic kinase signalling", Nature 411, 355-365 (2001).
288. B. P. Zhou et al. "Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells", Nat. Cell Biol. 3, 245-252 (2001).
289. B. J. Feldman and D. Feldman. "The development of androgen-independent prostate cancer", Nat. Rev. Cancer 1, 34-45 (2001).
290. R. Mukherjee et al. "Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists", Nature 386, 407-410 (1997).